web analytics
16.3 C
Munich
Saturday, May 28, 2022

Was Correction Overdue for TNI BIOTECH INC (OTCMKTS:TNIB) ?

TNI BIOTECH INC (OTCMKTS:TNIB) has seen a recent increase in trading volume and price after the stock hit an all-time low of $0.1305. Maybe this is the pivotal reversal shareholders have been praying for since the stock was $10 per share,.

TNIB made a spectacular run in late 2012 early 2013 from pennies a share to $10. The type of run that makes dreams come true for the smart investors who bought in early and cashed in their chips near the top.

The run was followed by months turned into a year of steady downward momentum that took the stock from $10 to pennies right back where it started. At the peak of the run TNIB had an absurd market valuation of $1 billion.

TNI BIOTECH INC (OTCMKTS:TNIB) is a biopharmaceutical company involved in manufacturing, distribution, and marketing of our rights to our immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system in fighting chronic and life threatening diseases. Our goal is to provide affordable sustainable health care in emerging nations where little or no treatments exist for many of these diseases.

To Find out the inside Scoop on TNIB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

TNIB therapies have been shown in clinical trials to stimulate the immune system in patients with cancer, autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, fibromyalgia, melanoma, prostate cancer, cervical cancer, and inflammatory bowel disease. The therapies may be used as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery and in combination with antibiotics or retroviral drug therapy in the treatment of a variety of infectious diseases, including patients with HIV/AIDS.

In June 2014, TNIB announced the signing of a distribution agreement for the non-exclusive distribution of Lodonal® into Malawi, Panama, Sri Lanka, Egypt, Malaysia and Haiti. With this sale, TNIB, through it is wholly owned subsidiary Airmed Biopharma Limited, will begin monthly shipments under the existing agreement. TNIB anticipates revenue of $1,800,000 dollars over the next twelve months.

Lodonal® is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient’s immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases with no toxic side effects.

Lodonal® competes in the advanced cancer and autoimmune drug market. Global Industry Analysis, Inc. recently released a comprehensive global report on the Autoimmune Disease Therapeutics market, which stated that the global market for Autoimmune Disease Therapeutics is projected to exceed US$77 billion by the year 2017, driven by the rising incidence of autoimmune complications worldwide. We believe that Lodonal® has demonstrated potential clinical and economic advantages over existing treatments for a number of chronic and acute autoimmune diseases, such as HIV/AIDS, certain cancers, rheumatoid arthritis, multiple sclerosis, Crohn’s Disease and inflammatory bowel disease.

We have a Monster Pick Coming. Subscribe Right Now!

On August 27, TNIB announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc.

Conclusion: TNIB made an absolutely spectacular run last year from pennies to $10 share. Since then the stock has come all the way back down where it started recently hitting a 52 week low of $0.1305.

Clearly TNIB was a very well-run promotion with the stock reaching an absurd $1 billion market valuation. Investors in the Company at anywhere near that valuation had to be worried when they looked at the books and saw no revenues to date, minimal cash and mounting short term date.

Now that TNIB has bottomed out and looks to have made a significant reversal many investors are accumulating. This is a stock that ran from pennies to $10 last year. Clearly this one knows how to move and many investors are accumulating here betting it will do just that. From current $24 million market valuation TNIB is a stock to watch.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in TNIB either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.